Voice Biomarker Innovator Canary Speech Raises $13M
Written by Sirish Dixit
Canary Speech, a Provo-based AI voice biomarker health tech company, raised $13 million in Series A funding led by Cortes Capital. The funds will support team expansion and growth. Canary's technology analyzes speech to detect mental health and neurological disorders early.
Canary Speech, a Provo-based AI-powered voice biomarker health tech company, has raised $13 million in Series A funding.
The funding round was led by Cortes Capital (Love’s Private Equity), with participation from Sorenson Communications, SMK, and Hackensack Meridian Health.
The company plans to use the funds to expand its team to support growth driven by advancements in artificial intelligence and the healthcare industry’s demand for more advanced tools.
Led by CEO Henry O’Connell, Canary Speech uses AI-powered voice biomarker technology for real-time patented vocal analysis to screen for mental health and neurological disorders. The technology captures and analyzes speech data within seconds to identify irregularities in behavioral and cognitive changes, often before current clinical screening standards or noticeable symptoms for conditions such as anxiety, depression, and dementia.
As an API-first company, Canary’s vocal biomarker technology has diverse applications within the healthcare industry. These include contact centers, ambient clinical listening, remote patient monitoring, and annual wellness checks. Ambient listening tools, which unobtrusively capture and analyze conversations in real-time, allow healthcare providers to focus on patient interactions while automatically documenting clinical notes.